The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.

ABSTRACT:

Background

Tumor molecular profiling from patients experiencing exceptional responses to systemic therapy may provide insights into cancer biology and improve treatment tailoring. This pilot study evaluates the feasibility of identifying exceptional responders retrospectively, obtaining pre-exceptional response treatment tumor tissues, and analyzing them with state-of-the-art molecular analysis tools to identify potential molecular explanations for responses.

Methods

Exceptional response was defined as partial (PR) or complete (CR) response to a systemic treatment with population PR or CR rate less than 10% or an unusually long response (eg, duration >3 times published median). Cases proposed by patients' clinicians were reviewed by clinical and translational experts. Tumor

SUBMITTER: Conley BA 

PROVIDER: S-EPMC7781457 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature